HEB - Hemispherx Biopharma, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue43792133197
Cost of Revenue1,1831,1081,5981,251
Gross Profit-746-1,016-1,465-1,054
Operating Expenses
Research Development4,0914,9737,8238,542
Selling General and Administrative6,5726,8317,1479,057
Non Recurring----
Total Operating Expenses11,84612,91216,56818,850
Operating Income or Loss-11,409-12,820-16,435-18,653
Income from Continuing Operations
Total Other Income/Expenses Net3,1505,3181,2051,203
Earnings Before Interest and Taxes-11,409-12,820-16,435-18,653
Interest Expense-139-139-3-11
Income Before Tax-8,259-7,502-15,230-17,450
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-8,259-7,502-15,230-17,450
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-8,259-7,502-15,230-17,450
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-8,259-7,502-15,230-17,450